171 related articles for article (PubMed ID: 12655794)
1. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
6. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
[TBL] [Abstract][Full Text] [Related]
10. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G
Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
[TBL] [Abstract][Full Text] [Related]
11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
15. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma.
Wos E; Olencki T; Tuason L; Budd GT; Peereboom D; Sandstrom K; McLain D; Finke J; Bukowski RM
Cancer; 1996 Mar; 77(6):1149-53. PubMed ID: 8635137
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
